ABHD13

Across TCGA pan-cancer cohorts, ABHD13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD13 data layer compared with 18 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ABHD13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SKCM, and UCEC are the cancer types where ABHD13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.153	0.663	.004	18	view →
SKCM	OS	Median	III,IV	0.072	0.814	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.887	0.303	.017	10	view →
COAD	DFS	Median	II,III,IV	0.159	0.554	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABHD13–LUAD (OS)

Open the LUAD breakdown →